Achieves Second Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases
09/04/2026 24:31
Nxera Pharma Co Ltd 4565.T: NXERA PHARMA CO - ACHIEVES SECOND DEVELOPMENT MILESTONE IN COLLABORATION WITH ELI LILLY TARGETING METABOLIC DISEASES Source text: ID:nTSph7a220 Further company coverage: 4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up